Research advances in therapeutics for neurofibromatosis type 2-associated vestibular schwannomas

Advances in Neurofibromatosis Research

Volumn , Issue , 2012, Pages 221-236

  Yates, Charles ^a   Welling, D Bradley ^a   Chang, Long Sheng ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885023511     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (80)

1. Welling, D.B.; Packer, M.D.; Akhmametyeva, E.M.; Chang, L.S. The Biology and genetics of vestibular schwannomas. (2008). Chapter 9. In: Bambakidis, N; Megerian, C; Porter, R; Spetzle (eds). Tumors of the Cerebellopontine Angle. Ontario: B.C. Decker Inc.
2. Evans, D.G.; Kalamarides, M.; Hunter-Schaedle, K.; Blakeley, J.; Allen, J.; Babovic-Vuskanovic, D.; Belzberg, A.; Bollag, G.; Chen, R.; DiTomaso, E.; et al. (2009). Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res, 15(16):5032-9.
3. Takenobu, A.; Okamoto, H.; Hirao, J.; Kurosaki, M.; Watanabe, T.; Hori, T.; Ohama E. (1993). Malignant nerve sheath tumor of the jugular foramen followed by meningeal dissemination in a patient with neurofibromatosis. Noshuyo Byori, 10(2):125-30.
4. Mut, M.; Cataltepe, O.; Soylemezoglu, F.; Akalan, N.; Ozgen, T. (2004). Radiation-induced malignant triton tumor associated with severe spinal cord compression. Case report and review of the literature. J Neurosurg, 100(3 Suppl Spine):298-302.
5. Balasubramaniam, A.; Shannon, P.; Hodaie, M.; Laperriere, N.; Michaels, H.; Guha, A. (2007). Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol, 9(4):447-53.
6. Chibbaro, S.; Herman, P.; Povlika, M.; George, B. (2008). Malignant trigeminal schwannoma extending into the anterior skull base. Acta Neurochir (Wien), 150(6):599-604.
7. Sordillo, P.P.; Helson, L.; Hajdu, S.I.; Magill, G.B.; Kosloff, C.; Golbey, R.B.; et al. (1981). Malignant schwannoma--clinical characteristics, survival, and response to therapy. Cancer, 47(10):2503-9.
8. Victoria, L.; McCulloch, T.M.; Callaghan, E.J.; Bauman, N.M. (1999). Malignant triton tumor of the head and neck: A case report and review of the literature. Head Neck, 21(7):663-70.
9. Trofatter, J.A.; MacCollin, M.M.; Rutter, J.L.; Murrell, J.R.; Duyao, M.P.; Parry, D.M.; Eldridge, R.; Kley, N.; Menon, A.G.; Pulaski, K. et al. (1993). A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell, 72(5):791-800.
10. Rouleau, G.A.; Merel, P.; Lutchman, M.; Sanson, M.; Zucman, J.; Marineau, C.; Hoang-Xuan, K.; Demczuk, S.; Desmaze, C.; Plougastel, B. et al. (1993). Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature, 363(6429):515-21.
11. Marosi, C.; Hassler, M.; Roessler, K.; Reni, M.; Sant, M.; Mazza, E.; et al. (2008). Meningioma. Crit Rev Oncol Hematol, 67(2):153-71.
12. Gusella, J.F.; Ramesh, V.; MacCollin, M.; Jacoby, L.B. (1999). Merlin: the neurofibromatosis 2 tumor suppressor. Biochim Biophys Acta,1423(2):M29-36.
13. McClatchey, A.I.; Giovannini, M. Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev, 19(19):2265-77.
14. Shaw, R.J.; Paez, J.G.; Curto, M.; Yaktine, A.; Pruitt, W.M.; Saotome, I.; et al. (2001). The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell, 1(1):63-72.
15. Surace, E.I.; Haipek, C.A.; Gutmann, D.H. (2004). Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene, 23(2):580-7.
16. Rong, R.; Surace, E.I.; Haipek, C.A.; Gutmann, D.H.; Ye, K. (2004). Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene, 23(52):8447-54.
17. Kissil, J.L.; Johnson, K.C.; Eckman, M.S.; Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. (2002). J Biol Chem, 277(12):10394-9.
18. Alfthan, K.; Heiska, L.; Gronholm, M.; Renkema, G.H.; Carpen, O. (2004). Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem, 279(18):18559-66.
19. Tang, X.; Jang, S.W.; Wang, X.; Liu, Z.; Bahr, S.M.; Sun, S.Y.; Brat, D.; Gutmann, D.H.; Ye, K. (2007). Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol, 9(10):1199-207.
20. Jin, H.; Sperka, T.; Herrlich, P.; Morrison, H. (2006). Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature, 442(7102):576-9.
21. Scoles, D.R. (2008). The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta, 1785(1):32-54.
22. Mautner, V.F.; Baser, M.E.; Kluwe, L. (1996). Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations. Hum Genet, 98(2):203-6.
23. Gutmann, D.H.; Hirbe, A.C.; Haipek, C.A. (2001). Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum Mol Genet, 10(14):1519-29.
24. Bruder, C.E.; Hirvela, C.; Tapia-Paez, I.; Fransson, I.; Segraves, R.; Hamilton, G.; Zhang, X.X.; Evans, D.G.; Wallace, A.J.; Baser, M.E. et al. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. (2001). Hum Mol Genet, 10(3):271-82.
25. Tsilchorozidou, T.; Menko, F.H.; Lalloo, F.; Kidd, A.; De Silva, R.; Thomas, H.; et al. (2004). Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. J Med Genet, 41(7):529-34.
26. Kluwe, L.; Nygren, A.O.; Errami, A.; Heinrich, B.; Matthies, C.; Tatagiba, M.; et al. (2005). Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer, 42(4):384-91.
27. Glasscock, M.E. 3rd; Woods, C.I.; Jackson, C.G.; Welling, D.B. (1989). Management of bilateral acoustic tumors. Laryngoscope, 99(5):475-84.
28. Welling, D.B.; Glasscock, M.E. 3rd; Woods, C.I.; Jackson, C.G. (1990). Acoustic neuroma: a cost-effective approach. Otolaryngol Head Neck Surg, 103(3):364-70.
29. Neff, B.A.; Wiet, R.M.; Lasak, J.M.; Cohen, N.L.; Pillsbury, H.C.; Ramsden, R.T.; Welling, D.B. (2007). Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Laryngoscope. 117(6):1069-72.
30. Grant, K.W.; Seitz, P.F. (2000). The use of visible speech cues for improving auditory detection of spoken sentences. J Acoust Soc Am, 108(3 Pt 1):1197-208.
31. McClatchey, A.I.; Saotome, I.; Ramesh, V.; Gusella, J.F.; Jacks, T. (1997). The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev, 11(10):1253-65.
32. Giovannini, M.; Robanus-Maandag, E.; van der Valk, M.; Niwa-Kawakita, M.; Abramowski, V.; Goutebroze, L.; Woodruff, J.M.; Berns, A.; Thomas, G. (2000). Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev, 14(13),1617-30.
33. Giovannini, M.; Robanus-Maandag, E.; Niwa-Kawakita, M.; van der Valk, M.; Woodruff, J.M.; Goutebroze, L.; et al. (1999). Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev, 13(8):978-86.
34. Hung, G.; Li, X; Faudoa, R.; Xeu, Z.; Kluwe, L.; Rhim, J.S.; et al. (2002). Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol, 20(3):475-82.
35. Lee, J.K.; Sobel, R.A.; Chiocca, E.A.; Kim, T.S.; Martuza, R.L. (1992). Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J Neurooncol, 14(2):101-12.
36. Charabi, S.; Rygaard, J.; Klinken, L.; Tos, M.; Thomsen, J. (1994). Subcutaneous growth of human acoustic schwannomas in athymic nude mice. Acta Otolaryngol, 114(4):399-405.
37. Stidham, K.R.; Roberson, J.B. Jr. (1997). Human vestibular schwannoma growth in the nude mouse: evaluation of a modified subcutaneous implantation model. Am J Otol. 18(5):622-6.
38. Chang, L.S.; Jacob, A.; Lorenz, M.; Rock, J.; Akhmametyeva, E.M.; Mihai, G.; et al. (2006). Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice. Laryngoscope, 116(11):2018-26.
39. Clark, J.J.; Provenzano, M.; Diggelmann, H.R.; Xu, N.; Hansen, S.S.; Hansen, M.R. (2008). The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol, 29(6):846-53.
40. Neff, B.A.; Voss, S.G.; Allen, C.; Schroeder, M.A.; Driscoll, C.L.; Link, M.J.; et al. (2009). Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice. Otol Neurotol, 30(1):105-11.
41. Welling, D.B.; Lasak, J.M.; Akhmametyeva, E.; Ghaheri, B.; Chang, L.S. (2002). cDNA microarray analysis of vestibular schwannomas. Otol Neurotol, 23(5):736-48.
42. Lasak, J.M.; Welling, D.B.; Akhmametyeva, E.M.; Salloum, M.; Chang, L.S. (2002). Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas. Laryngoscope, 112(9):1555-61.
43. Hanemann, C.O.; Bartelt-Kirbach, B.; Diebold, R.; Kampchen, K.; Langmesser, S.; Utermark, T. (2006). Differential gene expression between human schwannoma and control Schwann cells. Neuropathol Appl Neurobiol, 32(6):605-14.
44. Jacob, A.; Lee, T.X.; Neff, B.A.; Miller, S.; Welling, B.; Chang, L.S. (2008). Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma. Otol Neurotol, 29(1):58-68.
45. Lee, T.X.; Packer, M.D.; Huang, J.; Akhmametyeva, E.M.; Kulp, S.K.; Chen, C.S.; Giovannini, M.; Jacob, A.; Welling, D.B.; Chang, L.S. (2009). Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells, Eur J Cancer, 45(9):1709-20.
46. Dickersin, G.R. (1987). The electron microscopic spectrum of nerve sheath tumors. Ultrastruct Pathol, 11(2-3):103-46.
47. Hanemann, C.O. (2008). Magic but treatable? Tumours due to loss of merlin. Brain, 131(Pt 3):606-15.
48. Adlkofer, K.; Lai, C. (2000). Role of neuregulins in glial cell development. Glia, 29(2):104-11.
49. Fernandez-Valle, C.; Tang, Y.; Ricard, J.; Rodenas-Ruano, A.; Taylor, A.; Hackler E., Biggerstaff J, Iacovelli J. (2002). Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet, 31(4):354-62.
50. Doherty, J.K.; Ongkeko, W.; Crawley, B.; Andalibi, A.; Ryan, A.F. (2008). ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Otol Neurotol, 29(1):50-7.
51. Kaempchen, K.; Mielke, K.; Utermark, T.; Langmesser, S.; Hanemann, C.O. (2003). Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet, 12(11):1211-21.
52. Hansen, M.R.; Roehm, P.C.; Chatterjee, P.; Green, S.H. (2006). Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia, 53(6):593-600.
53. Hansen, M.R.; Clark, J.J.; Gantz, B.J.; Goswami, P.C. (2008). Effects of ErbB2 signaling on the response of vestibular schwannoma cells to gamma-irradiation. Laryngoscope, 118(6):1023-30.
54. Plotkin, S.R.; Singh, M.A.; O'Donnell, C.C.; Harris, G.J.; McClatchey, A.I.; Halpin, C. (2008). Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol, 5(8):487-91.
55. Mukherjee, J.; Kamnasaran, D.; Balasubramaniam, A.; Radovanovic, I.; Zadeh, G.; Kiehl, T.R.; Guha, A. (2009). Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). Cancer Res, 69(12):5099-107.
56. Xiao, G.H.; Gallagher, R.; Shetler, J.; Skele, K.; Altomare, D.A.; Pestell, R.G.; Jhanwar, S.; Testa, J.R. (2005). The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol, 25(6):2384-94.
57. Kissil, J.L.; Wilker, E.W.; Johnson, K.C.; Eckman, M.S.; Yaffe, M.B.; Jacks, T. (2003). Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell, 12(4):841-9.
58. Hirokawa, Y.; Tikoo, A.; Huynh, J.; Utermark, T.; Hanemann, C.O.; Giovannini, M.; et al. (2004). A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J, 10(1):20-6.
59. Yi, C.; Wilker, E.W.; Yaffe, M.B.; Stemmer-Rachamimov, A.; Kissil, J.L. (2008). Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res, 68(19):7932-7.
60. Wilhelm, S.M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J.M.; Lynch, M. (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther, 7(10):3129-40.
61. LoPiccolo, J.; Blumenthal, G.M.; Bernstein, W.B.; Dennis, P.A. (2008). Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat, 11(1-2):32-50.
62. Zhu, J.; Huang, J.W.; Tseng, P.H.; Yang, Y.T.; Fowble, J.; Shiau, C.W.; et al. (2004). From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res, 64(12):4309-18.
63. Johnson, A.J.; Smith, L.L.; Zhu, J.; Heerema, N.A.; Jefferson, S.; Mone, A.; Grever, M.; Chen, C.S.; Byrd, J.C. (2005). A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase-and Bcl-2-independent mechanism. Blood, 105(6):2504-9.
64. Tong, Z.; Wu, X.; Chen, C.S.; Kehrer, J.P. (2006). Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. Lung Cancer, 52(1):117-24.
65. Porchia, L.M.; Guerra, M.; Wang, Y.C.; Zhang, Y.; Espinosa, A.V.; Shinohara, M.; Thomsen J. (2007). 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phe nyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol, 72(5):1124-31.
66. Zhang, S.; Suvannasankha, A.; Crean, C.D.; White, V.L.; Johnson, A.; Chen C.S.; et al. (2007). OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res, 13(16):4750-8.
67. Kulp, S.K.; Chen, C.S.; Wang, D.S.; Chen, C.Y. (2006). Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res, 12(17):5199-206.
68. Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen CS, Chang LS, Welling DB, Jacob A. (2011). AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol, 13 [Epub ahead of print] PMID: 21778190.
69. Caye-Thomasen, P.; Baandrup, L.; Jacobsen, G.K.; Thomsen, J.; Stangerup, S.E. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope, 113(12), 2129-34.
70. Caye-Thomasen, P.; Werther, K.; Nalla, A.; Bog-Hansen, T.C.; Nielsen, H.J.; Stangerup, S.E.; et al. (2005). VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol, 26(1):98-101.
71. Saito, K.; Kato, M.; Susaki, N.; Nagatani, T.; Nagasaka, T.; Yoshida, J. (2003). Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol, 22(1):30-4.
72. Plotkin, S.R.; Stemmer-Rachamimov, A.O.; Barker, F.G. 2nd, Halpin, C; Padera, T.P., Tyrrell, A.; Sorensen, A.G.; Jain, R.K.; di Tomaso, E. (2009). Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med, 361(4):358-67.
73. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M. et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64(19):7099-109.
74. Neuhouser, M.L. (2004). Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer, 50(1):1-7.
75. Scalbert, A.; Manach, C.; Morand, C.; Remesy, C.; Jimenez, L. (2005). Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr, 45(4):287-306.
76. Moon, Y.J.; Wang, X.; Morris, M.E. (2006). Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol in Vitro, 20(2):187-210.
77. Suh, Y.; Afaq, F.; Johnson, J.J.; Mukhtar, H. (2009). A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis, 30(2):300-7.
78. Korutla, L.; Kumar, R. (1994). Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta, 1224(3):597-600.
79. Sagar, S.M.; Yance, D.; Wong, R.K. (2006). Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. Curr Oncol, 13(3):99-107.
80. Demestre, M.; Messerli, S.M.; Celli, N.; Shahhossini, M.; Kluwe, L.; Mautner, V.; Maruta, H. (2009). CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice. Phytother Res, 23(2):226-30.